Search results
Showing 166 to 180 of 1037 results for criteria
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
have been discharged from children's services (whether or not they meet criteria for adult services)? Any explanatory notes(if...
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.
Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.
View recommendations for MTG40Show all sections
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision? Any explanatory notes(if...
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.